Renin–angiotensin–aldosterone system inhibitors (RAASi) are guideline-recommended therapy for individuals with cardiorenal disease. They are associated with increased risk of hyperkalaemia, a common and life-threatening disorder for this population. RAASi-induced hyperkalaemia often leads to dose reduction or discontinuation, reducing cardiorenal protection. Guideline recommendations differ between specialties for the clinical management of hyperkalaemia. Using a modified Delphi method, we developed consensus recommendations for optimal management of hyperkalaemia in adults with cardiorenal disease.

中文翻译：

---

关于心肾范围内高钾血症最佳实践建议的国际德尔菲共识

肾素-血管紧张素-醛固酮系统抑制剂 (RAASi) 是指南推荐的治疗心肾疾病患者的药物。它们与高钾血症的风险增加有关，高钾血症是该人群常见且危及生命的疾病。RAASi 诱发的高钾血症通常会导致剂量减少或停药，从而降低心肾保护作用。高钾血症临床管理的指南建议因专业而异。我们使用改进的 Delphi 方法，为患有心肾疾病的成人高钾血症的最佳管理制定了共识建议。